Insurance coverage varies across New York, so it is worth checking with both your provider and insurer before starting
Morning administration may also be preferred by those who want to monitor for potential adverse effects during waking hours when they can respond appropriately
It depends on the pathway
Always consult a medical professional first
Results of the phase 3b TOGETHER-PsA trial showed ixekizumab administered together with tirzepatide in comorbid overweight or obese adults with psoriatic arthritis showed clinically meaningful improvement of psoriatic disease, physical function, weight reduction, & quality-of-life, with no new safety concerns Read the full results in Arthritis & Rheumatology Ixekizumab with Tirzepatide Improves Psoriatic Arthritis in Overweight Adults Results of the phase 3b TOGETHER-PsA trial showed ixekizumab administered together with tirzepatide in comorbid overweight or obese adults with psoriatic arthritis showed clinically meaningful improvement of psoriatic disease, physical function, weight reduction, & quality-of-life, with no new safety concerns Read the full results in Arthritis & Rheumatology To view or add a comment, sign in More Relevant Posts Super interesting results of Together PsA and the idea of combining anti-cytokine approaches with a modulator of the GLP1 axis
.svg)
